全文获取类型
收费全文 | 48284篇 |
免费 | 2504篇 |
国内免费 | 117篇 |
专业分类
耳鼻咽喉 | 764篇 |
儿科学 | 2014篇 |
妇产科学 | 845篇 |
基础医学 | 6175篇 |
口腔科学 | 1160篇 |
临床医学 | 3113篇 |
内科学 | 11356篇 |
皮肤病学 | 1573篇 |
神经病学 | 4121篇 |
特种医学 | 1333篇 |
外科学 | 7164篇 |
综合类 | 388篇 |
一般理论 | 16篇 |
预防医学 | 3933篇 |
眼科学 | 1302篇 |
药学 | 2979篇 |
中国医学 | 225篇 |
肿瘤学 | 2444篇 |
出版年
2023年 | 349篇 |
2022年 | 319篇 |
2021年 | 1196篇 |
2020年 | 597篇 |
2019年 | 1319篇 |
2018年 | 2108篇 |
2017年 | 1285篇 |
2016年 | 1163篇 |
2015年 | 1034篇 |
2014年 | 1266篇 |
2013年 | 2166篇 |
2012年 | 3579篇 |
2011年 | 4061篇 |
2010年 | 1973篇 |
2009年 | 1188篇 |
2008年 | 2950篇 |
2007年 | 3030篇 |
2006年 | 2785篇 |
2005年 | 2831篇 |
2004年 | 2658篇 |
2003年 | 2609篇 |
2002年 | 2291篇 |
2001年 | 1604篇 |
2000年 | 2101篇 |
1999年 | 1107篇 |
1998年 | 317篇 |
1997年 | 233篇 |
1996年 | 198篇 |
1995年 | 181篇 |
1994年 | 126篇 |
1993年 | 116篇 |
1992年 | 169篇 |
1991年 | 127篇 |
1990年 | 124篇 |
1989年 | 124篇 |
1988年 | 134篇 |
1987年 | 94篇 |
1986年 | 77篇 |
1985年 | 114篇 |
1984年 | 97篇 |
1983年 | 95篇 |
1982年 | 73篇 |
1981年 | 62篇 |
1980年 | 65篇 |
1979年 | 79篇 |
1978年 | 81篇 |
1977年 | 64篇 |
1976年 | 58篇 |
1975年 | 61篇 |
1973年 | 60篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
3.
4.
5.
6.
Rosario Gulias-Cañizo Anell Lagunes-Guillén Arturo González-Robles Erika Sánchez-Guzmán Federico Castro-Muñozledo 《Burns : journal of the International Society for Burn Injuries》2019,45(2):398-412
Background
Since recent reports have shown that (-)-Epigallocatechin-3-gallate (EGCG) could be used for treating proliferative and inflammatory disorders, we explored its use for the management of corneal chemical burns.Materials and methods
Initially, EGCG was assayed on the rabbit corneal epithelial cell line RCE1(5T5) to establish the best testing conditions, and to avoid unwanted outcomes in the experimental animals. Then, we studied its effects on cell proliferation, cell cycle progression and cell differentiation. Afterwards, we instilled EGCG in experimental grade II corneal alkali burns in mice, three times a day up to 21 days, and evaluated by slit lamp examination and histological sections of corneal epithelial, corneal endothelial and stromal edema, as well as the presence of inflammatory cells and neovascularization.Results
EGCG reduced cell growth and led to a decline in the proportion of proliferative cells in a concentration dependent manner. At 10 μM, EGCG promoted cell differentiation, an effect not related with apoptosis or cytotoxicity. When 10 μM EGCG was instilled in corneal alkali burns in mice three times a day up to 21 days, EGCG significantly reduced corneal opacity and neovascularization. The improved clinical appearance of the cornea was associated to a controlled epithelial growth; epithelial morphology was similar to that observed in normal epithelium and contrasted with the hyperproliferative, desquamating epithelium observed in control burn wounds. EGCG reduced corneal, stromal and endothelial edema, and wound inflammation.Conclusion
This work constitutes the first evidence for the use of EGCG in the acute phase of a corneal alkali burn, representing a possible novel alternative to improve patient outcomes as an add-on therapy. 相似文献7.
Focal hyperhidrosis secondary to eccrine naevus successfully treated with botulinum toxin type A 下载免费PDF全文
Eccrine naevus (EN) is a rare skin hamartoma included in the organoid group of epidermal naevi, histologically defined as focal hyperplasia and/or hypertrophy of eccrine glands. Clinically, EN usually presents as hyperhidrotic patches with no visible skin changes, frequently located on the forearms. The decision to treat EN or not usually depends on the grade of hyperhidrosis, but there is no therapeutic consensus because of the rarity of this condition. We present a case diagnosed as EN in an adult patient with severe localized hyperhidrosis, which was successfully treated with botulinum toxin. 相似文献
8.
Maria Gonzalez-Cao Cristina Carrera Juan Francisco Rodriguez Moreno Pedro Rodríguez-Jiménez Mónica Antoñanzas Basa Rosa Feltes Ochoa Teresa Puertolas Eva Muñoz-Couselo José Luis Manzano Ivan Marquez-Rodas Juan Martín-Liberal Ainara Soria Pilar Lopez Criado Almudena Garcia-Castaño Aram Boada Pablo Ayala de Miguel Susana Puig Guillermo Crespo Alfonso Berrocal 《Journal of the American Academy of Dermatology》2021,84(5):1412-1415
9.
10.
Lorena Martin-Morales Sara Manzano Maria Rodrigo-Faus Adrian Vicente-Barrueco Victor Lorca Gonzalo Núñez-Moreno Paloma Bragado Almudena Porras Trinidad Caldes Pilar Garre Alvaro Gutierrez-Uzquiza 《International journal of cancer. Journal international du cancer》2023,152(2):283-297
Matrix metalloproteinase-11 (MMP11) is an enzyme with proteolytic activity against matrix and nonmatrix proteins. Although most MMPs are secreted as inactive proenzymes and are later activated extracellularly, MMP11 is activated intracellularly by furin within the constitutive secretory pathway. It is a key factor in physiological tissue remodeling and its alteration may play an important role in the progression of epithelial malignancies and other diseases. TCGA colon and colorectal adenocarcinoma data showed that upregulation of MMP11 expression correlates with tumorigenesis and malignancy. Here, we provide evidence that a germline variant in the MMP11 gene (NM_005940: c.232C>T; p.(Pro78Ser)), identified by whole exome sequencing, can increase the tumorigenic properties of colorectal cancer (CRC) cells. P78S is located in the prodomain region, which is responsible for blocking MMP11's protease activity. This variant was detected in the proband and all the cancer-affected family members analyzed, while it was not detected in healthy relatives. In silico analyses predict that P78S could have an impact on the activation of the enzyme. Furthermore, our in vitro analyses show that the expression of P78S in HCT116 cells increases tumor cell invasion and proliferation. In summary, our results show that this variant could modify the structure of the MMP11 prodomain, producing a premature or uncontrolled activation of the enzyme that may contribute to an early CRC onset in these patients. The study of this gene in other CRC cases will provide further information about its role in CRC development, which might improve patient treatment in the future. 相似文献